S-W. Kim

1.9k total citations · 1 hit paper
75 papers, 1.3k citations indexed

About

S-W. Kim is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, S-W. Kim has authored 75 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 42 papers in Pulmonary and Respiratory Medicine and 10 papers in Molecular Biology. Recurrent topics in S-W. Kim's work include Lung Cancer Treatments and Mutations (37 papers), Colorectal Cancer Treatments and Studies (17 papers) and Lung Cancer Research Studies (13 papers). S-W. Kim is often cited by papers focused on Lung Cancer Treatments and Mutations (37 papers), Colorectal Cancer Treatments and Studies (17 papers) and Lung Cancer Research Studies (13 papers). S-W. Kim collaborates with scholars based in South Korea, United States and Japan. S-W. Kim's co-authors include Yong Kiel Sung, Yong‐Gil Kim, Chan Kyu Kim, Simon Rice, G. Paul Amminger, Miriam R. Schäfer, Michael Berk, Patrick D. McGorry, Gheeyoung Choe and So Yeon Park and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Cancer Research and Annals of Oncology.

In The Last Decade

S-W. Kim

71 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Recent advances in the development of gene delivery systems

2019 336 citations S-W. Kim et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S-W. Kim South Korea	17	469	424	239	163	117	75	1.3k
Ashwani Gupta India	19	811 1.7×	318 0.8×	148 0.6×	152 0.9×	89 0.8×	89	1.9k
Yun Hak Kim South Korea	24	796 1.7×	264 0.6×	288 1.2×	118 0.7×	130 1.1×	170	2.0k
Shinya Kojima Japan	24	314 0.7×	337 0.8×	235 1.0×	38 0.2×	252 2.2×	66	1.5k
Patrizio Bollero Italy	19	220 0.5×	154 0.4×	205 0.9×	82 0.5×	130 1.1×	91	1.2k
Alessandro Lanza Italy	27	267 0.6×	143 0.3×	113 0.5×	66 0.4×	148 1.3×	81	1.9k
Noriaki Yamamoto Japan	24	590 1.3×	323 0.8×	91 0.4×	166 1.0×	81 0.7×	126	1.7k
Julia Meyer United States	17	310 0.7×	259 0.6×	70 0.3×	48 0.3×	134 1.1×	46	1.2k
David M. Graham United States	22	451 1.0×	151 0.4×	62 0.3×	87 0.5×	88 0.8×	53	1.5k
Aránzazu Mediero Spain	28	665 1.4×	196 0.5×	63 0.3×	68 0.4×	113 1.0×	90	2.0k

Countries citing papers authored by S-W. Kim

Since Specialization

Citations

This map shows the geographic impact of S-W. Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S-W. Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S-W. Kim more than expected).

Fields of papers citing papers by S-W. Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S-W. Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S-W. Kim. The network helps show where S-W. Kim may publish in the future.

Co-authorship network of co-authors of S-W. Kim

This figure shows the co-authorship network connecting the top 25 collaborators of S-W. Kim. A scholar is included among the top collaborators of S-W. Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S-W. Kim. S-W. Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhu, Jiang, Chee Khoon Lee, Isamu Okamoto, et al.. (2025). LBA77 FLAURA2: Exploratory overall survival (OS) analysis in patients (pts) with poorer prognostic factors treated with osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) as first-line (1L) treatment (tx) for EGFR-mutated (EGFRm) advanced NSCLC. Annals of Oncology. 36. S1618–S1619.

Ahn, M-J., Sierra Cheng, S-W. Kim, et al.. (2025). 2O: SAVANNAH: Savolitinib (savo) + osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and METoverexpression (OverExp) and/or amplification (Amp) following progressive disease (PD) on osi. Journal of Thoracic Oncology. 20(3). S4–S5. 2 indexed citations

Kim, S-W., et al.. (2025). EP.08.22 Treatment Patterns and Clinical Outcomes in South Korean Patients With Unresectable Stage III EGFRm NSCLC Undergoing CRT. Journal of Thoracic Oncology. 20(10). S757–S757.

Ramalingam, Sundar, Mustafa Özgüroğlu, M-J. Ahn, et al.. (2025). LBA4: Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC): Updated overall survival (OS) analysis from the LAURA study. Journal of Thoracic Oncology. 20(3). S123–S124. 3 indexed citations

Özgüroğlu, Mustafa, M-J. Ahn, Xiaoyu Dong, et al.. (2024). 616P Osimertinib after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC): Post-progression outcomes from the phase III LAURA study. Annals of Oncology. 35. S1626–S1626. 1 indexed citations

Goto, Yasushi, Kōichi Goto, Toshio Kubo, et al.. (2023). 510MO Trastuzumab deruxtecan (T-DXd) in Asian patients (Pts) with human epidermal growth factor receptor 2 (HER2; ERBB2)-mutant (HER2m) metastatic non-small cell lung cancer (mNSCLC): Subgroup analysis of DESTINY–Lung02 (DL-02). Annals of Oncology. 34. S1666–S1667. 2 indexed citations

Kim, S-W., et al.. (2023). 60 CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) + cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy. Journal of Thoracic Oncology. 18(4). S39–S40. 19 indexed citations

Juan, Óscar, et al.. (2023). 1391P Capmatinib vs docetaxel as second- or third-line (2/3L) therapy in patients (pts) with METex14-mutated advanced NSCLC (aNSCLC): The GeoMETry-III trial. Annals of Oncology. 34. S797–S797. 1 indexed citations

Hong, Min Hee, Alexander I. Spira, Ki Hyeong Lee, et al.. (2023). 1333P A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations. Annals of Oncology. 34. S769–S769. 5 indexed citations

10.

Garon, Edward B., Byoung Chul Cho, Alexander Luft, et al.. (2022). 5MO Patient reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON. Annals of Oncology. 33. S29–S30. 2 indexed citations

11.

Kim, Hye Ryun, Ross A. Soo, Hideki Hayashi, et al.. (2022). 992P Updated analyses from the CROWN study of first-line lorlatinib vs crizotinib in Asian patients with ALK-positive non-small cell lung cancer (NSCLC). Annals of Oncology. 33. S1007–S1007. 3 indexed citations

12.

Ramalingam, Suresh S., S-W. Kim, Gregory J. Riely, et al.. (2021). 1231P Characterization and management of mobocertinib (TAK-788) induced skin toxicity in patients with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) who previously received platinum chemotherapy. Annals of Oncology. 32. S975–S975. 1 indexed citations

13.

Cho, Byoung Chul, Dongwook Kim, Jin Sun Lee, et al.. (2020). 1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC. Annals of Oncology. 31. S813–S813. 32 indexed citations

14.

Planchard, David, Nina Karaseva, S-W. Kim, et al.. (2020). 1401P Osimertinib plus platinum/pemetrexed in newly-diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study. Annals of Oncology. 31. S888–S888. 7 indexed citations

15.

Tan, Daniel Shao-Weng, M-J. Ahn, Herbert H. Loong, et al.. (2020). 299MO Efficacy and safety of entrectinib in an Asian population with NTRK fusion-positive (fp) solid tumours or ROS1-fp NSCLC. Annals of Oncology. 31. S1358–S1359. 2 indexed citations

16.

Tsuboi, Masahiro, Yi‐Long Wu, Jian He, et al.. (2020). 356MO Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence. Annals of Oncology. 31. S1378–S1378. 3 indexed citations

17.

Brahmer, Julie R., T-E. Ciuleanu, Michael Schenker, et al.. (2020). 67P Survival of responders to nivolumab (NIVO) + ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1. Annals of Oncology. 31. S1444–S1445. 3 indexed citations

18.

Zhou, C., Ying Cheng, You Lü, et al.. (2017). CNS response to osimertinib in Asian-Pacific patients (pts) with T790M-positive advanced NSCLC: data from an open-label Phase II trial (AURA17). Annals of Oncology. 28. v484–v484. 5 indexed citations

19.

Yu, Lei, et al.. (2001). Augmentation of myocardial transfection using TerplexDNA: a novel gene delivery system. Gene Therapy. 8(5). 349–353. 40 indexed citations

20.

Kim, HH, et al.. (1995). In situ extracorporeal shock wave lithotripsy for ureteral calculi: Investigation of the factors influencing on stone fragmentation and the appropriate session for changing treatment modality. Korean journal of urology. 36. 722–730. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact